Orthovita's bone loss repair patent upheld:
This article was originally published in Clinica
Executive Summary
The US Patent and Trademark Office has decided to reconfirm the patentability for a process of restoring a bone defect or deficiency by filling with osseous tissue. The patent in questions, No 5,204,106, is owned by Belgium-based FBFC International and exclusively licensed to Orthovita, a US manufacturer of bone growth materials. Orthovita recently received US FDA and European approval to market its BioGran bone growth material for certain periodontal and dental applications. US Biomaterials, a distributor of grafting material, had asked the US Patent Office for the re-examination.